Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Endocrine 2CNS 1

Conditions

Brain Neoplasms 2310Glioblastoma 2014Glioma 1399Central Nervous System Neoplasms 692Astrocytoma 667Neuroblastoma 647Gliosarcoma 480Neoplasms 405Oligodendroglioma 404Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 255Meningioma 229Recurrence 224Sarcoma 214Melanoma 206Neoplasm Metastasis 202Lung Neoplasms 199Ependymoma 199Neurofibromatosis 1 169Lymphoma 161Meningeal Carcinomatosis 138Osteosarcoma 134Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 106

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary leiomyomatosis and renal cell cancer × CNS × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡